EGFR and head and neck squamous cell carcinoma: Again, as EGFR is overexpressed in approximately 90% of HNSCC tumors [10]–[12], we checked the effect of erlotinib, an EGFR-targeting small molecule tyrosine kinase inhibitor, on the expression of EGFR in HNSCC cells.